Oberndorfer, F.; Moling, S.; Hagelkruys, L.A.; Grimm, C.; Polterauer, S.; Sturdza, A.; Aust, S.; Reinthaller, A.; Müllauer, L.; Schwameis, R.
Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data. J. Pers. Med. 2021, 11, 48.
https://doi.org/10.3390/jpm11010048
AMA Style
Oberndorfer F, Moling S, Hagelkruys LA, Grimm C, Polterauer S, Sturdza A, Aust S, Reinthaller A, Müllauer L, Schwameis R.
Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data. Journal of Personalized Medicine. 2021; 11(1):48.
https://doi.org/10.3390/jpm11010048
Chicago/Turabian Style
Oberndorfer, Felicitas, Sarah Moling, Leonie Annika Hagelkruys, Christoph Grimm, Stephan Polterauer, Alina Sturdza, Stefanie Aust, Alexander Reinthaller, Leonhard Müllauer, and Richard Schwameis.
2021. "Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data" Journal of Personalized Medicine 11, no. 1: 48.
https://doi.org/10.3390/jpm11010048
APA Style
Oberndorfer, F., Moling, S., Hagelkruys, L. A., Grimm, C., Polterauer, S., Sturdza, A., Aust, S., Reinthaller, A., Müllauer, L., & Schwameis, R.
(2021). Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data. Journal of Personalized Medicine, 11(1), 48.
https://doi.org/10.3390/jpm11010048
